ATAI Life Sciences N.V.
Research ATAI Life Sciences N.V. (ATAI) on Bullrun: market cap USD 2.74B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerATAI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.74B
- Financial periodQ1 2026
- RevenueUSD 954.00K
- Net income-USD 663.40M
- Free cash flow-USD 111.52M
Valuation Snapshot
latest market cap is USD 2.74B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.09M | -USD 660.05M | -USD 103.58M | n/a | -2.91 | USD 85.30M | USD 135.40M | USD 221.87M |
| FY2024 | USD 308.00K | -USD 149.27M | -USD 82.44M | n/a | -0.93 | USD 17.51M | USD 20.51M | USD 116.30M |
| FY2023 | n/a | n/a | n/a | n/a | -0.42 | USD 45.03M | USD 19.14M | USD 242.96M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.74B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.49B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 223.39M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 234.07M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 441.23M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.23B | n/a | n/a | n/a |
About ATAI Life Sciences N.V.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ATAI Life Sciences N.V.'s market cap?
ATAI Life Sciences N.V.'s market capitalization is USD 2.74B.
What does ATAI Life Sciences N.V. do?
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.